Key result
COVID-19 mRNA vaccine-associated myocarditis in 33 adolescents followed a mild, self-resolving clinical course with a median hospital stay of 2.3 days and no need for intensive care.
Why the study?
Myocarditis after COVID-19 mRNA vaccination had been reported in adolescents, prompting the need to describe initial diagnosis, imaging findings, and short-term outcomes in this population.
COVID-19 mRNA vaccine-associated myocarditis in adolescents appears to have a mild, self-resolving clinical course with favorable short-term outcomes.
No takes yet. Share an insight, caveat, or question.
Supports short-term reassurance in practice; leaves open need for larger studies on incidence and long-term outcomes.
Varma et al. (2022) conducted a letter in COVID-19 vaccine-associated myocarditis (n=33). COVID-19 mRNA vaccination was evaluated on Clinical course and short-term outcomes. COVID-19 mRNA vaccine-associated myocarditis in 33 adolescents followed a mild, self-resolving clinical course with a median hospital stay of 2.3 days and no need for intensive care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: